Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-045969
Filing Date
2025-05-08
Accepted
2025-05-08 10:18:26
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 8308
2 EXHIBIT 99.A tm2514463d2_ex99-a.htm EX-99.A 3954
3 EXHIBIT 99.B tm2514463d2_ex99-b.htm EX-99.B 29719
  Complete submission text file 0001104659-25-045969.txt   43413
Mailing Address 72 HAMMERSMITH ROAD LONDON X0 W14 8TH
Business Address 72 HAMMERSMITH ROAD LONDON X0 W14 8TH 44-0-20-3457 6900
Silence Therapeutics plc (Subject) CIK: 0001479615 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92205 | Film No.: 25924478
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O SILENCE THERAPEUTICS INC. 72 HAMMERSMITH ROAD LONDON X0 W14 8TH
Business Address
Griffiths Richard Ian (Filed by) CIK: 0001846370 (see all company filings)

Type: SCHEDULE 13D/A